Clinical Trial Update: Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial assessing the combination of docetaxel (Taxotere) and imatinib mesylate (Gleevec) in hormone-refractory prostate cancer was terminated, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Gleevec (Imatinib)
• Taxotere (docetaxel)

Snippet

Sponsor: NYU Langone Health | Conditions: Prostate Cancer, Prostatic Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2011-06-29